Mind Medicine (MMED.E) closed a bought deal short-form prospectus offering, issuing 27,381,500 units for $1.05 and brought in $28,750,575 today, according to a press release.

After the financing, the company strengthened their cash position to $50.1 million (or USD$37.8) to allow them to continue their progress with their clinical trials for medicines using psychedelics and experimental therapies.

“The strong institutional investor interest for this oversubscribed financing demonstrates the vast appetite for companies pursuing clinical trials of psychedelic medicines with the FDA and other regulatory bodies. With our sights set on a NASDAQ up-listing, this fresh funding will further assist the MindMed team in our mission to build the most diverse development pipeline of psychedelic inspired medicines and experiential therapies for patients,” said J.R. Rahn, the co-founder and co-CEO of MindMed.

The next step for MMED given the proceeds of the offering include investment in its research and clinical developments, including its 18-MC addiction treatment program using experimental drugs like ibogaine, LSD, microdose program for adult ADHD, Project Lucy, which is focused on LSD experiential therapy for anxiety disorders. They have partnerships with the University Hospital Basel Liechti Lab and the NYU Langone Health for a psychedelic medicine research training program. Also, they intend to use the funds for general working capital and corporate development purposes.

Each unit comprises one subordinate voting share of the company and one-half of one subordinate voting share purchase warrant. Each warrant gives the holder the right purchase one subordinate voting share at $1.40 until Oct. 30, 2023. The warrants will be listed for trading on the NEO Exchange under the symbol MMED.WS, subject to all the usual approvals.

—Joseph Morton

Written By:

Joseph Morton

Joseph is a Vancouver-based author and journalist with both a communications degree and journalism diploma (and a few novels) under his belt. His joie de vivre is to spin difficult technical topics into more human-centric narratives. Buy him a coffee and he'll talk your ear off for hours about privacy issues, blockchain, cryptocurrency and martial arts. Don't talk to him if you're either a tomato, a bully, or if you're not a fan of either 1984 or Tender is the Night. No. You can still talk to him. Just be prepared to be told why you're wrong.

More By This Author
Tags:
Health Science
Pharmaceuticals
ibogaine
LSD
Mind Medicine
MindMEd
MMED.E
NYU Langone Health
psychedelic medicine
psychedelic research
psychedelic therapy
University Hospital Basel Liechti Lab
0 0 votes
Article Rating
Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments
0
Would love your thoughts, please comment.x
()
x